Akagera Medicines Inc, a clinical-stage biopharmaceutical company developing lipid nanoparticle (LNP) therapeutics and vaccines for infectious diseases, announced on Wednesday that the Gates Foundation has expanded its grant supporting the company's dendritic cell-targeted LNP mRNA vaccine for the prevention of tuberculosis (TB).
This award adds USD7,806,414 in funding, bringing the total committed under the grant to USD9,791,826.
The grant continues a preclinical feasibility and development programme first funded in 2023. The expanded funding will support GMP manufacturing of clinical trial material and the IND-enabling toxicology studies ahead of a future regulatory filing and before a first-in-human (FIH) Phase 1 clinical trial.
Akagera's vaccine candidate pairs mRNA-encoded Mycobacterium tuberculosis antigens with an LNP engineered to preferentially deliver its payload to dendritic cells, the immune system's most potent antigen-presenting cells. By directing antigen expression to these cells, the approach is designed to drive the strong, durable T-cell responses believed to be central to protection against TB, while potentially enabling lower doses and improved tolerability.
Roche Diagnostics supplies molecular testing instruments to support Ebola response in the DRC
QIAGEN completes US QIAstat-Dx bloodstream infection portfolio with FDA clearance
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
Immuron signs US distribution deal for PROIBS
Charles River and Medigen collaborate on next-generation enterovirus vaccine development
Roche expands cyclospora testing portfolio to support US public health response